Characteristics and Reporting of Number Needed to Treat, Number Needed to Harm, and Absolute Risk Reduction in Controlled Clinical Trials, 2001-2019

被引：12
作者：
Elliott, Marissa H. [1 ]
Skydel, Joshua J. [2 ]
Dhruva, Sanket S. [3 ]
Ross, Joseph S. [4 ]
Wallach, Joshua D. [5 ]
机构：
[1] Yale Sch Publ Hlth, Dept Chron Dis Epidemiol, New Haven, CT USA
[2] Tufts Univ, Sch Med, Boston, MA 02111 USA
[3] Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA USA
[4] Yale Sch Med, Dept Internal Med, New Haven, CT USA
[5] Yale Sch Publ Hlth, Dept Environm Hlth Sci, 60 Coll St,4th Floor,Room 411, New Haven, CT 06510 USA
来源：
JAMA INTERNAL MEDICINE | 2021年 / 181卷 / 02期
关键词：
D O I：
10.1001/jamainternmed.2020.4799
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
This cross-sectional study assesses the trends and characteristics of absolute measure reporting in highly cited medical journals from 2001 to 2019.
引用
收藏
页码：282 / 284
页数：3
相关论文
共 50 条
[31]   Number Needed to Treat and Number Needed to Harm analysis of the zuranolone phase 2 clinical trial results in major depressive disorder [J].
Arnaud, Alix ;
Suthoff, Ellison ;
Stenson, Katie ;
Werneburg, Brian ;
Hodgkins, Paul ;
Bonthapally, Vijayveer ;
Jonas, Jeffrey ;
Meyer, Kellie ;
O'Day, Ken .
JOURNAL OF AFFECTIVE DISORDERS, 2021, 285 :112-119
[32]   Clinical Assessment of Lurasidone Benefit and Risk in the Treatment of Bipolar I Depression Using Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed [J].
Citrome, Leslie ;
Ketter, Terence A. ;
Cucchiaro, Josephine ;
Loebel, Antony .
NEUROPSYCHOPHARMACOLOGY, 2013, 38 :S359-S361
[33]   Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed [J].
Citrome, L. ;
Ketter, T. ;
Cucchiaro, J. ;
Loebel, A. .
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2014, 17 :54-54
[34]   Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed [J].
Citrome, Leslie ;
Ketter, Terence A. ;
Cucchiaro, Josephine ;
Loebel, Antony .
JOURNAL OF AFFECTIVE DISORDERS, 2014, 155 :20-27
[35]   Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed [J].
Ketter, T. A. ;
Citrome, L. ;
Cucchiaro, J. ;
Loebel, A. .
BIPOLAR DISORDERS, 2013, 15 :92-92
[36]   Using both "relative risk reduction" and "number needed to treat" in evaluating primary and secondary clinical trials of lipid reduction [J].
Moriarty, PM .
AMERICAN JOURNAL OF CARDIOLOGY, 2001, 87 (10) :1206-+
[37]   Clinical statistics for primary care practitioners: Part II - Absolute risk reduction, relative risk, relative risk reduction, and number needed to treat [J].
McHugh, Mary L. .
JOURNAL FOR SPECIALISTS IN PEDIATRIC NURSING, 2008, 13 (02) :135-138
[38]   The Number Needed to Treat: 25 Years of Trials and Tribulations in Clinical Research [J].
Suissa, Samy .
RAMBAM MAIMONIDES MEDICAL JOURNAL, 2015, 6 (03)
[39]   Lumateperone for the Treatment of Schizophrenia: Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed br br [J].
Citrome, Leslie ;
Durgam, Suresh ;
Edwards, John B. ;
Davis, Robert E. .
JOURNAL OF CLINICAL PSYCHIATRY, 2023, 84 (02)
[40]   Daridorexant for patients with chronic insomnia disorder: number needed to treat, number needed to harm, and likelihood to be helped or harmed [J].
Chalet, Francois-Xavier ;
Luyet, Pierre-Philippe ;
Rabasa, Cristina ;
Vaillant, Cedric ;
Saskin, Paul ;
Ahuja, Ajay ;
Citrome, Leslie .
POSTGRADUATE MEDICINE, 2024, 136 (04) :396-405
12345